Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.
Women with antiphospholipid syndrome (APS), a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnancy-related complications, including miscarriage. We have previously shown that C5a induction of tissue factor (TF) expression in neutrophils contributes to respiratory burst, trophoblast injury, and pregnancy loss in mice treated with aPL. Here we analyzed how TF contributes to neutrophil activation and trophoblast injury in this model. Neutrophils from aPL-treated mice expressed protease-activated receptor 2 (PAR2), and stimulation of this receptor led to neutrophil activation, trophoblast injury, and fetal death. An antibody specific for human TF that has little impact on coagulation, but potently inhibits TF/Factor VIIa (FVIIa) signaling through PAR2, inhibited aPL-induced neutrophil activation in mice that expressed human TF. Genetic deletion of the TF cytoplasmic domain, which allows interaction between TF and PAR2, reduced aPL-induced neutrophil activation in aPL-treated mice. Par2-/- mice treated with aPL exhibited reduced neutrophil activation and normal pregnancies, which indicates that PAR2 plays an important role in the pathogenesis of aPL-induced fetal injury. We also demonstrated that simvastatin and pravastatin decreased TF and PAR2 expression on neutrophils and prevented pregnancy loss. Our results suggest that TF/FVIIa/PAR2 signaling mediates neutrophil activation and fetal death in APS and that statins may be a good treatment for women with aPL-induced pregnancy complications.
Redecha
Patricia
P
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA.
Franzke
Claus-Werner
CW
Ruf
Wolfram
W
Mackman
Nigel
N
Girardi
Guillermina
G
D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000276:immunology / Q000494:pharmacology; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000276:immunology / Q000503:physiopathology*; D004195:Disease Models, Animal; D015942:Factor VIIa / Q000378:metabolism*; D005260:Female; D005313:Fetal Death / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D017353:Gene Deletion; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018375:Neutrophil Activation; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D011247:Pregnancy; D017382:Reactive Oxygen Species / Q000378:metabolism; D044463:Receptor, PAR-1 / Q000172:deficiency; D044464:Receptor, PAR-2 / Q000235:genetics / Q000378:metabolism*; D016897:Respiratory Burst / Q000187:drug effects; D015398:Signal Transduction; D019821:Simvastatin / Q000494:pharmacology; D013925:Thromboplastin / Q000235:genetics / Q000276:immunology / Q000378:metabolism*
D017152:Antibodies, Antiphospholipid; D007074:Immunoglobulin G; D017382:Reactive Oxygen Species; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D013925:Thromboplastin; D019821:Simvastatin; D015942:Factor VIIa